Key result
Anticoagulation is linked to reduced cognitive decline in AF, but randomized trial proof is lacking.
Why the study?
Although studies link atrial fibrillation with cognitive decline and suggest anticoagulation may reduce this risk, whether anticoagulation prevents cognitive decline and dementia remains unproven in randomized trials.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Patients with atrial fibrillation may be able to reduce their risk of cognitive impairment and dementia by taking their oral anticoagulation medication and having a healthy lifestyle.”
“What we saw is a little frightening because we saw that almost 20% of the population decreased their MoCA score by two points during the trial. These are very young patients, [mean age] just 53, highly educated, with no diabetes, no hypertension, no heart failure.”
“This trial answers a really important question, that there's no role for expanding our current indication for anticoagulation.”
May link AF to cognitive decline; hypothesis-generating and requires confirmation before guiding practice.
Numerous vascular risk factors and vascular diseases contribute to cognitive impairment and dementia. Many studies and registries show an association of atrial fibrillation (AF) with cognitive impairment, cognitive decline, and dementia. This is true for vascular dementia and Alzheimer's disease. The assumed multifactorial mechanisms include ischemic stroke, both apparent and silent, cerebral microinfarcts, cerebral hemorrhage, and reduced cerebral blood flow. A number of retrospective observational and prospective studies support that anticoagulation in patients with AF may reduce the risk of cognitive decline and dementia. This holds for both vitamin K antagonists (e.g., warfarin) and direct oral anticoagulants. However, it still remains unproven if anticoagulation reduces cognitive decline and dementia in AF patients based on randomized trials.
No takes yet. Share an insight, caveat, or question.
Diener et al. (2019) conducted a review in Atrial fibrillation. Anticoagulation was evaluated on Cognitive decline and dementia. Observational studies suggest anticoagulation may reduce cognitive decline and dementia in atrial fibrillation, but this remains unproven by randomized trials.
Synapse has enriched 10 related papers. Consider them for comparative context: